New combo aims to boost transplant success in tough lymphoma
NCT ID NCT07451652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two chemotherapy drugs (gemcitabine and oxaliplatin) plus a low dose of the immunotherapy epcoritamab in 10 people whose diffuse large B-cell lymphoma has come back or not responded to prior treatment. Participants must be eligible for a stem cell transplant. The goal is to see if this approach improves response rates and is safe enough to avoid hospitalization during the first treatment cycle.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario "Dr. José Eleuterio González"
RECRUITINGMonterrey, Nuevo León, 64640, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- New drug cocktail aims to tackle tough lymphoma
- Radiation and immunotherapy team up against hard-to-treat lymphoma